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ABSTRACT
Introduction The aim of the study was to develop and 
validate a clinical prediction rule (CPR) for foot ulceration in 
people with diabetes.
Research design and methods Development of a CPR 
using individual participant data from four international 
cohort studies identified by systematic review, with 
validation in a fifth study. Development cohorts were from 
primary and secondary care foot clinics in Europe and 
the USA (n=8255, adults over 18 years old, with diabetes, 
ulcer free at recruitment). Using data from monofilament 
testing, presence/absence of pulses, and participant 
history of previous ulcer and/or amputation, we developed 
a simple CPR to predict who will develop a foot ulcer within 
2 years of initial assessment and validated it in a fifth study 
(n=3324). The CPR’s performance was assessed with C- 
statistics, calibration slopes, calibration- in- the- large, and a 
net benefit analysis.
Results CPR scores of 0, 1, 2, 3, and 4 had a risk of ulcer 
within 2 years of 2.4% (95% CI 1.5% to 3.9%), 6.0% (95% 
CI 3.5% to 9.5%), 14.0% (95% CI 8.5% to 21.3%), 29.2% 
(95% CI 19.2% to 41.0%), and 51.1% (95% CI 37.9% to 
64.1%), respectively. In the validation dataset, calibration- 
in- the- large was −0.374 (95% CI −0.561 to −0.187) 
and calibration slope 1.139 (95% CI 0.994 to 1.283). The 
C- statistic was 0.829 (95% CI 0.790 to 0.868). The net 
benefit analysis suggested that people with a CPR score 
of 1 or more (risk of ulceration 6.0% or more) should be 
referred for treatment.
Conclusion The clinical prediction rule is simple, using 
routinely obtained data, and could help prevent foot ulcers 
by redirecting care to patients with scores of 1 or above. 
It has been validated in a community setting, and requires 
further validation in secondary care settings.
INTRODUCTION
Diabetes- related foot ulcers have severe 
consequences for the individual and health-
care systems providing foot care.1 Some 
ulcers lead to lower extremity amputation 
and ulcers have been linked with higher 
rates of mortality.2 Moreover, diabetes- related 
amputations are now increasing in young 
and middle- aged adults.3 In 2016, there were 
130 000 people with diabetes discharged from 
a US hospital with a lower extremity ampu-
tation.4 Estimated costs of treating ulcers 
vary from $10 000 to $35 000 per ulcer,5 and 
the annual direct costs in the USA alone of 
$176 billion, of which up to a third are related 
to the lower extremity.6 Similar costs per 
capita are seen globally,7 8 and the National 
Significance of this study
What is already known about this subject?
 ► Foot ulcers can lead to amputation and are costly to 
healthcare providers.
 ► Prediction of who will develop an ulcer means pre-
ventative therapies can be targeted appropriately.
 ► Current prediction models do not give precise risk 
estimates but a descriptive term instead, for exam-
ple, ‘intermediate risk’, which is hard to interpret.
What are the new findings?
 ► A simple, validated clinical prediction rule that quan-
tifies risk with scores 0 to 4 using the sum of:
Score 1 if insensitive to a 10 g monofilament.
Score 1 if any pedal pulse is absent.
Score 2 if there is history of previous ulcer or 
amputation.
 ► Risks of developing an ulcer for each score are:
Score 0—risk is 2.4% (95% CI 1.4% to 3.9%).
Score 1—risk is 6.0% (95% CI 3.5% to 9.5%).
Score 2—risk is 14% (95% CI 8.5% to 21%).
Score 3—risk is 29% (95% CI 19% to 41%).
Score 4—risk is 51% (95% CI 38% to 64%).
 ► Patients with a score of 1 or more could benefit from 
preventative treatment.
How might these results change the focus of 
research or clinical practice?
 ► Health professionals will be able to quickly and eas-
ily estimate risk of foot ulceration and so direct pre-
ventative therapies at those most likely to benefit.
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Health Service in England could save £250 million per 
year if the prevalence of foot ulceration was reduced by 
one third.1
Since the early 1990s, researchers have been devel-
oping tools to predict the risk of a diabetes- related foot 
ulceration or lower extremity amputation. These tools 
vary in complexity and include a range of patient data.9 
For example, the QDiabetes tool will calculate risk of 
amputation or blindness within the next 10 years, though 
it does not give risk of foot ulceration. Seven predictive 
tools for foot ulcer (including the American Diabetes 
Association, the University of Texas Foot Risk System, 
and the International Working Group on the Diabetic 
Foot risk classification systems) were tested in a popula-
tion of 446 people in Portugal. The models all demon-
strated relatively high levels of accuracy with C- statistics 
between 0.75 and 0.86. However, the number of elements 
required by each predictive model varied from 4 to 15. 
This variation is reflected in current diabetes clinical 
guidelines, which recommend the use of between 8 and 
10 individual elements from the patients’ history or test 
results, or different combinations of the same, for risk 
assessment.10–12 None of these predictive models gives a 
quantified risk, but a descriptive term such as ‘high risk’ 
or a recommendation such as ‘refer to foot clinic’.
Certain interventions have been shown to reduce the 
incidence of foot ulcers. A recent systematic review and 
meta- analysis found some evidence of effective interven-
tions to prevent foot ulceration. Meta- analyses of dermal 
infrared thermometry (relative risk 0.41 (95% CI 0.19, 
0.86)), complex interventions (relative risk 0.59 (95% CI 
0.38, 0.90), and custom- made footwear and offloading 
insoles (relative risk 0.53 (95% CI 0.33, 0.85)) all reduced 
the incidence of foot ulcers.13 Given this existing knowl-
edge of predisposing factors for foot ulceration and the 
availability of preventative interventions, our aim was 
to develop and validate a prognostic model and subse-
quent clinical prediction rule (CPR) to provide a risk 
estimate for an individual using his or her own data. 
The CPR should be accurate, simple to use, inexpensive, 
and produce a quantified risk of foot ulceration within 
a meaningful timeframe, for patients in primary and 
secondary care settings.
RESEARCH DESIGN AND METHODS
Source of data
This PODUS 2020 (Prediction of Diabetic foot Ulcer-
ations) project used individual participant data (IPD) 
from the PODUS 2015 project, which identified predic-
tors of foot ulceration in diabetes by systematic review 
and meta- analysis (see the online supplemental mate-
rial for details of PODUS 2015).14 The search strategies 
for Medline and Embase were rerun to find new studies 
published since 2015 and searched to May 2017. We iden-
tified one eligible study but a request for data was unsuc-
cessful.15 The PODUS 2020 inclusion criteria were:
 ► Studies that recruited people 18 years old or older 
with a diagnosis of diabetes.
 ► Participants were ulcer- free at time of recruitment (or 
if the study recruited some individuals with a current 
ulcer, it was possible to remove those individuals from 
the analysis), participants with a history of previous 
ulcer were eligible.
 ► Predictors of foot ulcer were assessed at baseline.
 ► Foot ulcer presence/absence was ascertained at 
follow- up.
Data from four cohort studies were used to develop the 
prognostic model and subsequent CPR.16–19 Data from 
a fifth cohort study, only available remotely via a Safe 
Haven facility, were used for external validation.10 20 The 
validation dataset was an electronic register, which had 
taken data from General Practice records and Informa-
tion Services Division NHS Scotland. The other PODUS 
2015 studies were either no longer available21 or did not 
have the required predictors.22–25
All studies were assessed for their risk of bias using 
the Prediction model Risk of Bias Assessment Tool 
(PROBAST).26 Recruitment dates ranged from May 1995 
to November 2007 in the development datasets, and the 
last follow- up date was December 2008. In the validation 
dataset, recruitment dates ranged from January 2001 to 
December 2006 and the final follow- up date was 2007. 
These studies are described extensively elsewhere.14
Participants
Of the four studies used for model development, two 
studies collected data from people who received care in 
UK community settings16 17 and two collected data from 
people in hospital foot clinics set in mainland Europe 
and the USA.18 19 The validation dataset had data from a 
UK electronic health register. Participants met the above 
criteria and received standard care for the setting.
Outcome
The outcome was any definition of foot ulceration as 
used by the contributing studies occurring within 2 years 
of baseline, as assessed by podiatrists or self- report ques-
tionnaires. The largest contributing study,16 with 6478 
participants comprising 78% of the total model develop-
ment dataset, had data on whether an ulcer had devel-
oped within 2 years from baseline, but not the precise 
date of ulceration. The other development and valida-
tion studies either gave time to ulceration or date of last 
follow- up, so that their data could be harmonized with 
the largest dataset.16
In three of the development datasets,16 17 19 the assess-
ment of outcome was blinded to predictors where 
possible. One of the predictors included amputation, 
which cannot be hidden from the assessor of ulcer 
outcome.
Selection of predictors
We chose three binary predictors for inclusion in prog-
nostic model and subsequent CPR based on their clinical 











are: first published as 10.1136/bm





3BMJ Open Diab Res Care 2021;9:e002150. doi:10.1136/bmjdrc-2021-002150
Epidemiology/Health services research
plausibility, availability, and testing in PODUS 2015 (see 
the online supplemental material).14 The three predic-
tors were (a) insensitivity to a 10 g monofilament, (b) an 
absent pedal pulse in either foot, and (c) previous history 
of ulceration or amputation.
Healthcare professionals carried out the test of touch 
sensation using a 10 g monofilament by applying the 
monofilament to the plantar aspect of the foot at a variety 
of sites. Participants then confirmed whether they felt the 
monofilament.
Healthcare professionals palpated two pulses in each 
foot, the dorsalis pedis and the posterior tibial pulses. 
However, a minority may be missing the dorsalis pedis 
pulse and be healthy.27
Previous history of ulceration or amputation was ascer-
tained either at initial assessment or from patient records. 
Patients were test- positive for previous history if either a 
foot ulcer or a lower extremity amputation had occurred 
prior to baseline data collection.
Statistical analyses methods—handling of predictors
The studies varied in the data recorded for insensitivity to 
10 g monofilaments and absent pedal pulses. For monofil-
aments, the number and place of sites on the foot tested 
by monofilament varied between studies. For pulses, 
some studies gave the total number of pulses per person, 
and others had recorded the absence/presence of the 
two individual pulses on each foot. However, for consis-
tency across studies, the following coding was adopted:
 ► Insensitivity to monofilaments was coded as 1 if the 
participant was insensate anywhere on the foot and 
0 if the participant could feel the monofilament at 
all sites.
 ► Absent pulses was coded as 1 if any of the four pulses 
(two on each foot) were missing and 0 if all four were 
present.
Previous history (ulcer and amputation) was consist-
ently coded in the different studies. Data on previous 
foot ulceration and previous amputation were combined 
because of the association of amputation with ulcera-
tion—they both suggest a propensity to ulcerate.28 For 
the prognostic model analysis, previous history was coded 
as 1 if the participant had a previous ulcer or amputa-
tion, and 0 if the participant had never had an ulcer or 
amputation.
Summary statistics were calculated for all the predic-
tors and an extensive description of all the datasets can 
be found elsewhere.14
Statistical analyses methods—underlying statistical model
The prediction model was logistic regression with the 
binary outcome of ulcer by 2 years. The predictors were 
monofilaments, pulses, and previous history of ulcer or 
amputation, which were forced into the model regard-
less of statistical significance. We checked with shrinkage 
factors that the size of the dataset and number of 
outcomes were adequate to fit the model. See the online 
supplemental material for details.
Statistical analyses methods—conversion of the prognostic 
model to a CPR
A general method for converting a prognostic model to 
a CPR is described by Steyerberg.29 In essence, the coef-
ficients of the prediction model are used to generate a 
scoring system (see the online supplemental material), 
by rounding coefficients and creating risk groups.
Statistical analyses methods—validation of predictive 
performance
For each participant in the validation dataset,10 20 we 
calculated the CPR score from the individual’s results for 
monofilaments, pulses, and previous history.
For each score, the actual risk of ulcer in the validation 
dataset was compared with the predicted risk of ulcer. 
Discrimination was assessed by calculating the C- statistic 
and visual examination of a receiver operating character-
istic (ROC) plot. A perfectly discriminating CPR would 
have a C- statistic of 1, while a CPR with no discrimination 
beyond chance would have a C- statistic of 0.5. Calibra-
tion was assessed with calibration- in- the- large, calibration 
slope, and calibration plots.29 A perfectly calibrated CPR 
would have a calibration slope of 1 and a calibration- in- 
the- large of 0.
The CPR is a simplification of the prognostic model 
and so may result in a loss of information. Hence, the 
performance of the prognostic model was compared with 
the CPR score in the validation dataset.
Statistical analyses methods—net benefit and decision curve
Finally, we conducted a net benefit analysis to investi-
gate how useful the CPR could be in practice.30 The net 
benefit analysis compared a ‘treat all’ and ‘treat none’ 
strategy to ‘treat some’ where who does and does not 
receive treatment is decided by the CPR score. The net 
benefit analysis indicated whether the CPR could have a 
clinical impact and was assessed with decision curves.30
Reporting and software
This study adhered to the Transparent Reporting of 
a multivariable prediction model for Individual Prog-
nosis or Diagnosis (TRIPOD) reporting guidelines and 
include a TRIPOD checklist in the online supplemental 
Table 1 Demographic results for the development studies 
(Abbott, Crawford, Monteiro- Soares, Pham)16–19 and the 






mean±SD Men, N (%)
Abbott 61.3±13.2 8.2±8.2 3515 (53.2)
Crawford 70.5±10.0 8.8±8.4 611 (51.2)
Monteiro- 
Soares
64.3±10.4 15.8±10.4 164 (45.6)
Pham 58.3±12.5 13.9±10.8 124 (50.0)
All development 62.7±13.1 8.8±8.6 4414 (52.5)
Leese 65.1±13.1 6.8±7.8 1931 (56.6)
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material.31 Software used were SAS V.9.4 ( www. sas. com) 
and R V.3.4.2 (https:// cran. r- project. org/) for all anal-
yses. The pROC,32 meta,33 and rms34 packages in R were 
used.
RESULTS
Results of the critical appraisal with the PROBAST tool 
are given in the online supplemental material. Overall, 
studies were considered to be at a low risk of bias and 
applicable to the research purpose. In one development 
dataset and the validation dataset, outcome was assessed 
with knowledge of the predictors.10 18 20
Participants
Participant flow diagrams for four studies are given in 
the online supplemental material. These show how many 
participants did and did not have complete data. One 
study did not need a flow diagram as it had complete data 
for the outcome and all three predictors.18 The number 
of patients in the development datasets was 8404, and 
the number who contributed to the analyses was 8255 
(98%). The percentage with complete data in the valida-
tion dataset was 3324 (97.4%), again high enough not to 
require multiple imputation.
The median age of the participants was older in the vali-
dation dataset (67 years) versus development (64 years) 
datasets. The percentage of men ranged from 45.6% to 
56.6% in the five datasets (see table 1).
The community- based studies16 17 had smaller percent-
ages of people insensitive to monofilaments or with 
previous history compared with the secondary care- 
based studies,18 19 but broadly comparable percentages 
with absent pulses (see table 2). The risk of ulcer in the 
community- based studies16 17 was at least 10% lower than 
the secondary based care based studies. The results from 
the validation dataset10 20 were more similar to the results 
from the community based studies16 17 than the secondary 
care based studies.18 19
Prognostic model development
The number of patients from the development datasets 
used in the logistic regression models was 8255, with 430 
people developing ulcers and 7825 people remaining 
ulcer- free.
On the log- odds scale, for the logistic regression model 
using the three clinical predictors, the coefficient for 
monofilaments was 1.11, for pulses 0.70, and previous 
history 1.95. These correspond to ORs of 3.00 (95% CI 
2.39 to 3.76), 2.01 (95% CI 1.62 to 2.51), and 7.02 (95% 
CI 5.40 to 9.13), respectively. The estimate of baseline 
risk was 2.2% (95% 1.7% to 2.8%). See the online supple-
mental material for the underlying logistic regression 
equation that forms the prognostic model.
CPR development
After examination of the prognostic model coefficients 
and the corresponding risks of developing an ulcer given 
in the online supplemental material, a CPR was created 
based on the following scoring system:
 ► Score 1 if insensitive to a 10 g monofilament.
 ► Score 1 if any pedal pulse is absent.
 ► Score 2 if there is history of previous ulcer or 
amputation.
This CPR therefore gives scores from zero to four. The 
modeling procedure was repeated (see the online supple-
mental material) with CPR score as the only predictor. 
Baseline risk was 2.4% (95% CI 1.7% to 3.4%), and the 
OR for CPR score was 2.57 (95% CI 2.36 to 2.81). Risk of 
ulceration for each score is given in table 3.
Shrinkage factors for both the prognostic model and 
the CPR were very close to 1, showing that the sample 
size was adequate for the analyses (see the online supple-
mental material for details).
Validation of the CPR in the validation dataset
In the validation dataset, there were 3324 participants 
with suitable data, of whom 128 had an ulcer by 2 years 
and 3196 remained ulcer- free.10 20 The validation plot 
suggests excellent calibration of risks in the lower risk 
groups, but slight miscalibration at higher risk groups 
(see figure 1); however, the net benefit analysis below 
would recommend the same clinical pathway despite any 
miscalibration. The calibration slope was 1.139 (95% CI 
0.994 to 1.283) and calibration- in- the- large was −0.374 
(95% CI −0.561 to −0.187). See the online supplemental 
Table 2 Predictor and outcome data in the development studies (Abbott, Crawford, Monteiro- Soares, Pham)16–19 and 







% (n) missing at 
least one foot 
pulse
% (n) with 
previous ulcer 
or amputation
% (n) with ulcer 
outcome at 
2 years
% (n) with 
complete 
data
Abbott 6603 19.4 (1278) 29.6 (1957) 4.7 (312) 4.4 (291) 98.1 (6478)
Crawford 1193 22.3 (266) 18.8 (224) 7.2 (86) 1.9 (23) 98.5 (1175)
Monteiro- Soares 360 46.1 (166) 20.3 (73) 38.1 (137) 14.4 (52) 100 (360)
Pham 248 74.6 (185) 14.5 (36) 71.4 (177) 27.8 (69) 97.6 (242)
All development studies 8404 22.5 (1895) 27.2 (2290) 8.5 (712) 5.2 (435) 98.2 (8255)
Leese 3412 20.7 (707) 14.0 (478) 5.7 (196) 3.9 (133) 97.4 (3324)
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material for calibration results in the prognostic model, 
which are very similar to those of the CPR.
Examination of the ROC curve (see the online supple-
mental material) suggests very little loss of discrimination 
performance when using the CPR compared with the 
prognostic model. The area under the ROC curve for the 
CPR was 0.829 (95% CI 0.790 to 0.868) and for the prog-
nostic model was 0.834 (95% CI 0.794 to 0.873).
Potential impact of the CPR
The net benefit analysis aimed to balance the risk of not 
offering treatment to people who would develop an ulcer 
against treating people who would not develop an ulcer. 
If the overall risk of ulceration is very high, there will be 
a benefit to treating everyone. If the overall risk of ulcer-
ation is very low, it may not be worth offering treatment 
to anyone. Between these two extremes, the net benefit 
analysis suggests that offering treatment to those people 
with a risk of 6% or more, that is, a CPR score of 1 or more, 
would correctly weigh risk of ulceration against unneces-
sary treatment (see online supplemental material).
CONCLUSION
A CPR was developed and validated to predict foot 
ulceration within 2 years in people with diabetes. The 
data came from a large international dataset, which 
was assembled using a systematic review and IPD meta- 
analyses.14 35 The three predictors that form the CPR 
are easy to collect during patient foot examinations, are 
usually recorded in health records and therefore this 
CPR can be applied at the point of care. The 10 g mono-
filament test is inexpensive and widely used in foot risk 
assessments (eg, https:// gpnotebook. com/ simplepage. 
cfm? ID= x2020063010498191128), and the assessment 
of pedal pulses is a standard part of routine foot care. A 
history of lower extremity amputation or foot ulceration 
is both well- known risk factors and is highly likely to have 
been recorded in patient’s health records across different 
healthcare settings.
Other advantages of this CPR are that it requires very 
little calculation by the end- user and quantifies a person’s 
risk of foot ulceration over a 2- year timescale in a way that 
is easy to understand. Simplicity, ease- of- use, and cost are 
all important factors that can affect whether or not a CPR 
is used in clinical practice. This is especially true in the 
context of the global health environments, where a CPR 
using only three predictors may be particularly useful. 
Furthermore, an analysis of routinely collected foot risk 
assessment data conducted by the wider research group 
found only 5% of people at low risk of foot ulceration 
changed their risk score during a 2- year period.36 This 
suggests that biennial, as opposed to annual foot risk 
assessment for those at low risk of foot ulceration may 
be adequate.36 If this simplified CPR was used biennially 
to assess risk of foot ulceration, the burden on diabetes 
services across primary care, community and hospital 
settings could be greatly reduced.
CPRs are a form of Clinical Decision Support System 
(CDSS), but these can be underused unless they are inte-
grated into existing clinical systems. For example, CDSSs 
requiring computing software need to be embedded 
into the IT systems and the healthcare professionals 
are obliged to use in routine care.37 38 A CPR that can 
be used independently of electronic equipment is of 
value because of the very wide range of IT availability 
for healthcare professionals across all clinical settings 
worldwide. In this manuscript, there is a print version of 
the CPR for use in the consulting room (online supple-
mental material), and any healthcare professional could 
learn the risk estimates for each individual score quickly. 
However, the CPR could also be integrated into existing 
electronic foot screening programs such as SCI- diabetes 
(https://www. sci- diabetes. scot. nhs. uk/).
The CPR was developed using individual patient data 
from three different countries and healthcare systems 
to make a better assessment of the generalizability and 
Table 3 Population- based probability of ulcer at 2 years 





ulcer at 2 years 95% CI
0 4646 0.024 (0.014 to 0.039)
1 2406 0.060 (0.035 to 0.095)
2 676 0.140 (0.085 to 0.213)
3 358 0.292 (0.192 to 0.410)
4 169 0.511 (0.379 to 0.641)
CPR, clinical prediction rule.
Figure 1 Calibration plot from the external validation of the 
CPR. Gray line indicates perfect calibration; black curve is 
the estimated calibration curve. The five groups correspond 
to CPR scores of 0–4, and vertical lines show the width of 
the 95% CI. CPR, clinical prediction rule.
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applicability across different healthcare settings and 
populations.39 The authors are unaware of any other 
CPRs for foot ulceration in diabetes that are equally 
simple to use and that have had such a robust process of 
development and validation.
The four international cohort studies which were 
used in the analyses were designed specifically to iden-
tify predictive factors of foot ulceration in people with 
diabetes. These structured datasets had very few missing 
values, a characteristic of routinely collected datasets 
which can undermine the process of validation for prog-
nostic models.40
Strengths and limitations
Despite being derived from only three binary predic-
tors, the discrimination and calibration of the CPR were 
excellent when externally validated in a UK population. 
There was slight miscalibration in those with the highest 
risks, but this is acceptable if clinical risk thresholds are 
likely to be much lower. Indeed, the net benefit analysis 
suggests that the use of the CPR to identify people who 
score 1 or above (ie, predicted risk of 6% or above) for 
subsequent treatment with preventative interventions 
could bring greater clinical benefits than either treat- all 
or treat- none strategies and thus is likely to have clinical 
utility in practice. Further validation in countries other 
than the UK, Portugal, or the USA would be welcome.
The weaknesses of the CPR and the underlying statis-
tical model lie in its simplicity; as it has only three binary 
predictors, it will not give predictions across the entire 0 
to 1 probability range. However, there are no prognostic 
models that predict foot ulceration with 100% accuracy 
and all comprise more sophisticated and expensive tests 
than this CPR. Also, many outcomes in diabetes are 
dependent on self- care, and in particular, the mainte-
nance of a tight HbA1c and a body mass index (BMI) 
lower than 27. Individuals can exert some control over 
these parameters. HbA1c has a known association with 
the development of peripheral neuropathy (the main 
etiology for foot ulceration in diabetes).41 Initially, HbA1c 
and BMI were considered for the model in PODUS 2015; 
however, neither were collected in the largest study.
As CPRs are not treatments in themselves, they do 
not directly influence clinical outcomes unless they are 
linked to clinical decision thresholds. The net benefit 
analysis shows that the CPR has the potential to have clin-
ical utility when a score of one or above is used to trigger 
treatment, but further evaluation is required where 
preventative interventions are targeted at those with a 
score of one or more. As death has also been linked to 
foot ulceration, ideally, an impact study would account 
for those participants who died before the end of the 
2 years’ follow- up and would analyze time- to- ulceration 
events and incorporate a competing risk model.
The use of this CPR in conjunction with effective preven-
tative interventions could improve patient outcomes by 
reducing the number of foot ulcers and generate finan-
cial savings for the NHS. The simplicity of the CPR means 
that the cost implications of implementing it in clinical 
practice are minimal.
The CPR was developed and validated in a large inter-
national dataset, but an evaluation of its clinical impact in 
different patient populations would assess its therapeutic 
impact. This should be assessed in a prospective compar-
ative study, preferably a randomized controlled trial.
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